Josep M. Gatell - Concepedia

Author

Josep M. Gatell

Also Known As

Adrian Curran, B. Clotet, Gatell, J, I. Bravo, J Gatell, J M Gatell, J. M. Gatell, J.-M. Gatell, J.M. Gatell, Josep Gatell

140

Publications

7.1K

Citations

H-Index

101

Concepts

All Affiliations

Universitat de Barcelona Hospital Clínic de Barcelona Consorci Institut D'Investigacions Biomediques August Pi I Sunyer Universitat Autònoma de Barcelona IrsiCaixa

About

Josep M. Gatell is an author at Universitat de Barcelona specializing in medicine, hiv, and infection control.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	31	3.4K
2	Public Health	5	5	497
3	Health Sciences	4	4	300
4	Arts	1	1	100
5	Natural Sciences	1	1	32

Josep M. Gatell

Publications

5.6K

Citations

H-Index

Page 1

	Year	Citations
Incidence, Risk, and Prognosis Factors of Nosocomial Pneumonia in Mechanically Ventilated Patients Antoní Torres, Roberto Aznar, Josep M. Gatell, American Review of Respiratory Disease AsthmaIntensive Care UnitVentilationClinical EpidemiologyPrognosis Factors	1990	926
Nosocomial Pneumonia Rosa Celis, Antoní Torres, Josep M. Gatell, CHEST Journal	1988	690
Re-intubation increases the risk of nosocomial pneumonia in patients needing mechanical ventilation. Antoní Torres, Josep M. Gatell, Elena Guadalupe Corella Aznar, American Journal of Respiratory and Critical Care Medicine AsthmaPrior BronchoscopyVentilationClinical EpidemiologyPatient Safety	1995	686
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials Pedro Cahn, Juan Sierra Madero, José Ramón Arribas, The Lancet Hiv/aids CounsellingTreatment And PreventionWeek 48Clinical EpidemiologyClinical Trials	2018	371
Nosocomial Bacteremia in a Large Spanish Teaching Hospital: Analysis of Factors Influencing Prognosis Josep M. Gatell, Antoni Trilla, X Latorre, Clinical Infectious Diseases Antimicrobial SusceptibilityHealth SciencesAntibioticsDrug ResistanceNosocomial Bacteremia	1988	142
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial Jean‐Michel Molina, Kathleen Squires, Paul E. Sax, The Lancet HIV Treatment And PreventionAntiviral Drug DevelopmentClinical TrialsAntiviral TherapyNon-inferiority Trial	2018	140
Impact of Switching from Human Immunodeficiency Virus Type 1 Protease Inhibitors to Efavirenz in Successfully Treated Adults with Lipodystrophy Estebán Martínez, Miguel A García-Viejo, J. L. Blanco, Clinical Infectious Diseases	2000	139
Treatment Intensification with Raltegravir in Subjects with Sustained HIV-1 Viraemia Suppression: A Randomized 48-Week Study Josep M. Llibre, María J. Buzón, Marta Massanella, Antiviral Therapy	2011	122
Infection of Hemodialysis Catheters: Incidence and Mechanisms Jaume Almirall, Juli agrave n Gonzalez, Jordi Rello, American Journal of Nephrology DialysisDialysis TherapySurgeryHealthcare-associated InfectionY Catheter Segments	1989	107
Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides Josep M. Gatell, F Ferran, V. Araujo, Antimicrobial Agents and Chemotherapy Drug SafetyAminoglycoside Serum LevelsAuditory ToxicityMedicineDrug Resistance	1987	100

Page 1